



Pacira Pharmaceuticals, Inc. to Participate in RBC Capital Markets Global Healthcare Conference

February 21, 2012

PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2012-- [Pacira Pharmaceuticals, Inc.](http://www.pacira.com) (Nasdaq: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to participate in a panel titled "New Developments in Neurology" at the RBC Capital Markets Global Healthcare Conference on Tuesday, Feb. 28, 2012, at 2:35 p.m. EST at the New York Palace Hotel & Conference Center in New York City.

About Pacira

Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was approved for administration into the surgical site to produce postsurgical analgesia by the U.S. Food and Drug Administration in October 2011. EXPAREL and two other commercially available products utilize the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at <http://www.pacira.com>.

Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3570
Chief Financial Officer